ACT LISINOPRIL TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Verfügbar ab:

ACTAVIS PHARMA COMPANY

ATC-Code:

C09AA03

INN (Internationale Bezeichnung):

LISINOPRIL

Dosierung:

10MG

Darreichungsform:

TABLET

Zusammensetzung:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100/500

Verschreibungstyp:

Prescription

Therapiebereich:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0121550001; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2018-06-12

Fachinformation

_______________________________________________________________________________________________
_ACT LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 43 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ACT_ _LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
Canada, L5N 6J5
Control Number: 208042
Date of Revision:
September 20, 2017
_______________________________________________________________________________________________
_ACT LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 43 _
_ _
_ _
_PR _
ACT_ _LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in the treatment of
hypertension, congestive heart failure and following myocardial
infarction in hemodynamically
stable patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor
substance, angiotensin II. Inhibition of ACE results in decreased
plasma angiotensin II, which
leads to increased plasma renin activity (due to removal of negative
feedback of renin release)
and decreased aldosterone secretion. Although the latter decrease is
small, it results in a small
increase in serum potassium. In patients treated with lisinopril and a
thiazide diuretic there was
essentially no change in serum potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of
lisinopril is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNA